Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pediatric Cancer Research topic
No spam. Unsubscribe anytime.
Legislators and families seek state trust fund to boost pediatric cancer research
Summary
Lawmakers and bereaved families urged the Joint Committee on Public Health to advance bills creating a trust fund to support pediatric cancer research and care, arguing federal and pharmaceutical investment has lagged and survivors face long-term harms from treatments developed decades ago.
Legislators and families asked the Joint Committee on Public Health to create a state trust fund to support pediatric cancer research, care and treatment innovation, saying federal funding and commercial incentives have left childhood cancers underfunded and children reliant on outdated therapies.
"Cancer is the number one cause of death by disease in children in The United States," Sen. O'Connor said while introducing Senate Bill 16-02 and the companion House measure (H 2434). He told the committee the bill would create a trust fund appropriated through the annual budget to finance research aimed at pediatric cures and better treatments.
Parents described the human toll of limited pediatric-specific therapies. Meryl Summers, whose daughter Adelia died of diffuse midline glioma, described the absence of effective drugs and the devastating course of universally fatal pediatric brain tumors: "There is yet to be 1 FDA approved drug to target this cancer," she said. "This is the agony and pain that I continue to live with and what my community continues to live with for the rest of our lives."
Other speakers, including bereaved families and advocacy groups such as the American Childhood Cancer Organization and American Cancer Society advocates, urged the committee to provide sustainable, state-level funding because pharmaceutical investment in pediatric oncology is limited and federal grants are insufficient. Gaudably supporters said the fund could complement federal dollars and leverage Massachusetts' research institutions to accelerate pediatric drug development.
What happened next: Sponsors requested a favorable recommendation; the committee took testimony but no committee-level vote was recorded at the hearing.
Ending: Sponsors and families urged the committee to move the bill forward so the Commonwealth could provide a dedicated, predictable funding stream for pediatric cancer research and care.
